|
KMID : 1001020180160030097
|
|
Journal of Urologic Oncology
2018 Volume.16 No. 3 p.97 ~ p.102
|
|
|
Precision Medicine in Castration-Resistant Prostate Cancer
|
|
Kim Won-Tae
Yun Seok-Joong
Kim Wun-Jae
|
|
|
Abstract
|
|
|
|
Prostate cancer is usually managed by androgen deprivation therapy after failure of primary treatment. However, such therapies are only temporarily effective in prostate cancer patients, and the most patients experience the progression to castration-resistant prostate cancer (CRPC). Docetaxel chemotherapy is conventional effective treatment for CRPC but has many adverse effects. In CRPC patients, treatment decisions were not typically base on the recognitions of inter-individual differences. Therefore, there are growing interests for precision medicine in CRPC. In this review, we summarized the precision medicine such as candidate target genes and potential therapies in CRPC.
|
|
|
KEYWORD
|
|
|
Prostatic neoplasms, Precision medicine, Prostatic neoplasms, Castration-resistant
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|